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A Systematic Review and Meta-Analysis of the Efficacy
and Safety of Intermittent Preventive Treatment of
Malaria in Children (IPTc)
Anne L. Wilson*, on behalf of the IPTc Taskforce"
London School of Hygiene and Tropical Medicine, London, United Kingdom
Abstract
Background: Intermittent preventive treatment of malaria in children less than five years of age (IPTc) has been investigated
as a measure to control the burden of malaria in the Sahel and sub-Sahelian areas of Africa where malaria transmission is
markedly seasonal.
Methods and Findings: IPTc studies were identified using a systematic literature search. Meta-analysis was used to assess
the protective efficacy of IPTc against clinical episodes of falciparum malaria. The impact of IPTc on all-cause mortality,
hospital admissions, severe malaria and the prevalence of parasitaemia and anaemia was investigated. Three aspects of
safety were also assessed: adverse reactions to study drugs, development of drug resistance and loss of immunity to
malaria. Twelve IPTc studies were identified: seven controlled and five non-controlled trials. Controlled studies
demonstrated protective efficacies against clinical malaria of between 31% and 93% and meta-analysis gave an overall
protective efficacy of monthly administered IPTc of 82% (95%CI 75%–87%) during the malaria transmission season. Pooling
results from twelve studies demonstrated a protective effect of IPTc against all-cause mortality of 57% (95%CI 24%–76%)
during the malaria transmission season. No serious adverse events attributable to the drugs used for IPTc were observed in
any of the studies. Data from three studies that followed children during the malaria transmission season in the year
following IPTc administration showed evidence of a slight increase in the incidence of clinical malaria compared to children
who had not received IPTc.
Conclusions: IPTc is a safe method of malaria control that has the potential to avert a significant proportion of clinical
malaria episodes in areas with markedly seasonal malaria transmission and also appears to have a substantial protective
effect against all-cause mortality. These findings indicate that IPTc is a potentially valuable tool that can contribute to the
control of malaria in areas with markedly seasonal transmission.
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Introduction
Intermittent preventive treatment of malaria (IPT) refers to the
administration of a full therapeutic course of an anti-malarial drug
to the whole of a population at risk, whether or not they are known
to be infected, at specific times, with the aim of preventing
mortality or morbidity from malaria [1]. IPT with sulphadoxine-
pyrimethamine (SP) is recommended by the WHO for use in
pregnant women (IPTp) and has recently been recommended by
the WHO for use in infants (IPTi), delivered alongside vaccines
within the context of the routine Expanded Programme on
Immunisation [2]. The decision by WHO to recommend IPTi in
areas where there is a significant malaria burden in infants and
where parasites are still sensitive to SP was made on the basis of
data including a pooled analysis of six IPTi studies which
demonstrated a 30% protective efficacy (PE) against episodes of
clinical malaria [3]. In areas of markedly seasonal malaria
transmission, such as the Sahel and sub-Sahel regions of Africa,
the main burden of malaria is in older children rather than infants,
and the risk of clinical malaria is restricted largely to a few months
each year [4,5]. In such areas, administration of IPT to children
several times during the seasonal peak in malaria transmission
(IPTc) has been investigated as a method of preventing malaria.
A Cochrane review published in 2008 reviewed the efficacy and
safety of chemoprophylaxis and IPT in children [6]. However,
although there is some overlap in the mechanism of protection
provided by chemoprophylaxis and IPT, these two approaches set
out to produce different blood concentration profiles and the
efficacy and safety of the two methods may differ. Since the
Cochrane review was undertaken, additional IPTc studies have
been conducted in different settings using several different drug
regimens. A systematic review and meta-analysis was therefore
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carried out to review new and existing data on the safety and
efficacy of IPTc administered seasonally to children under five
years of age. We specifically reviewed randomised controlled trials
that assessed the efficacy of IPTc against clinical malaria, severe
malaria, all-cause hospital admissions, Plasmodium falciparum
parasitaemia and anaemia when administered to children under
five years of age compared to placebo or no intervention. The
same studies were also used to assess the effect of IPTc on the
prevalence of markers of resistance to SP, as well as any rebound
effect in clinical malaria or anaemia in the year following IPTc
administration. Non-controlled studies were used additionally to
assess the efficacy of IPTc against all-cause mortality and to assess
the toxicity of the drugs used.
Methods
Search Strategy and Selection Criteria
A systematic literature search for IPTc studies (published,
unpublished and ongoing) was carried out on 25th March 2009
and updated on 19th August 2010. A single investigator (ALW)
developed and conducted the search. Studies were identified using
database searches, citation searches of selected articles and contact
with investigators. The electronic databases searched were:
Pubmed (1965-present), Web of Science (1970-present), and
Global Health (1910-present). Articles in English, German or
French were selected for review and no date restrictions were
applied to the search. The search was conducted using free-text
terms and standardised subject terms appropriate to the specific
database. Combinations of the following search terms were used;
intermittent, prevention, presumptive, season, therapy/treatment,
malaria and mass drug administration (Table S1). Ongoing and
completed clinical trials were identified through searches of clinical
trial databases [7,8].
Study eligibility was assessed by a single investigator (ALW) in
an un-blinded manner. Studies were retained if they met the
following criteria; i) seasonal administration of more than one
therapeutic course of anti-malarial drugs, whether or not subjects
were known to be infected, ii) study subjects were children, aged
less than 5 years, resident in a malaria endemic area, and, iii) the
objective of the study was evaluation of the effect of drug
administration on clinical malaria (with parasitological confirma-
tion). Studies which enrolled children older than 5 years were
included if data on children under 5 years were available for
analysis. All study designs were accepted, although only controlled
studies were used for analysis of primary efficacy outcomes.
Studies were excluded if their aim was to evaluate; i) the effect of a
sustained protective drug concentration against infection (chemo-
prophylaxis), or, ii) the effect of drug administration on
interruption of transmission (mass drug administration). Studies
in population subgroups such as anaemic children were also
excluded.
Data Extraction and Outcome Measures
Data from eligible studies was extracted based on the intention-
to-treat principle into a purpose built database by a single
investigator (ALW) (Excel, Microsoft, 2007). We did not have
access to data from individual children and, instead, combined
results taken from published papers were used. Investigators were
contacted directly if any information was unclear or not specified
in the published articles.
Clinical malaria was defined as an illness accompanied by an
axillary temperature of greater than or equal to 37.5uC or a history
of fever within the previous 24 or 48 hours and the presence of
asexual forms of P. falciparum parasitaemia at any density. An
alternative definition of clinical malaria using a locally defined
threshold concentration of P. falciparum parasitaemia was also used
for comparison. Severe malaria was defined as per the WHO
definition [9]. Anaemia was defined as a haemoglobin (Hb)
concentration less than 8g/dL or an haematocrit (Hct) of less than
25%. Parasitaemia was defined as the presence of asexual forms of
P. falciparum at any density. Molecular markers of SP resistance
assessed were the dhfr triple (51, 59, 108) mutations and the dhps
437 mutation, associated with resistance to pyrimethamine and
sulphones respectively. Adverse events (AE) and Serious Adverse
Events (SAE) were defined as per standard ICH definitions [10].
All trials used in the meta-analysis, whether published or
unpublished, had been approved by an ethics committee. The risk
of bias in the studies was assessed by a single investigator (ALW) in
an un-blinded manner using a tool developed by the Cochrane
Collaboration (focusing on specific domains including sequence
generation, allocation concealment, blinding, incomplete outcome
data and selective outcome reporting) [11]. Due to the small
number of studies identified, trials were not excluded based on
quality assessment and sensitivity analysis was not performed. For
the same reason, we were not able to formally assess for
publication bias.
Data Analysis
The effect of IPTc on malaria incidence (total number of
episodes) was expressed as a rate ratio. Person time at risk was
expressed in years (Person Years at Risk, PYAR) and was defined
as date of exit from the study minus date of enrolment into the
study. Date of exit for children who died was the date of death and
was defined as the date of the last contact with active or passive
malaria surveillance systems if a child was lost to follow up. Person
time at risk was reduced by 28 days (21 days in two studies [12,13])
for each episode of clinical malaria treated according to national
guidelines with an effective anti-malarial drug, thus reducing the
likelihood of recrudescence affecting the rate ratio. Only crude
rates were used, as opposed to those adjusted for covariates, such
as usage of insecticide treated bednets (ITN) or age. Confidence
intervals (CI) were calculated using an approximate standard error
obtained from the summary data on the total number of clinical
malaria episodes and PYAR. 95% CI and P-values were
calculated using standard formulae [14]. Protective efficacy was
calculated as PE= 12(Rate ratio of clinical malaria during the
intervention period)6100%. The difference between rates in the
IPTc and control arms was calculated. Due to the heterogeneity of
the efficacy estimates from the studies, a summary effect measure
was calculated using random effect meta-analysis with inverse-
variance weights. Forest plots also depict a summary effect
measure calculated using fixed effect meta-analysis for compari-
son. Fixed effect meta-analysis considers that variation between
studies is due purely to random variation. Random effect meta-
analysis assumes a different underlying effect for each study and
takes this into account as an additional source of variation,
resulting in a summary effect measure with wider CI. Where
studies are heterogeneous it is more appropriate to use a random
effect model [15]. Heterogeneity between trials was quantified
using the I2 statistic [16]. The effect of IPTc on the prevalence of
anaemia and of parasitaemia, as well as the mean Hb or Hct
concentration was assessed and 95% CI and two-sided P-values
were calculated using standard methods [14]. Deaths occurring
during the intervention period were expressed per 1000 children
who received the first dose of at least one course of IPTc and per
1000 PYAR, with the 95% CI and P-value for the corresponding
relative risk and rate ratio calculated using standard methods [14].
The most common AEs were pooled across studies for each IPTc
A Systematic Review and Meta-Analysis of IPTc
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regimen and expressed per 1000 courses of IPTc delivered.
Incidence of AEs was then compared to that in the control arms
using a z-test. Statistical analysis was conducted using Excel
(Microsoft, 2007) and STATA 10 (StataCorp, Texas, U.S.A.). This
review has been reported according to PRISMA guidelines [17,18]
(Table S2).
Results
Characteristics of Studies Identified
The systematic literature search identified seven controlled
IPTc studies [12,13,19,20,21,22,23] and a further five studies
which were not controlled [24,25,26,27,28] (Figure 1). Charac-
teristics of controlled and non-controlled studies are shown in
Table 1 and Table 2, respectively. Studies which were excluded
from the review are described in Table S3.
All seven controlled trials were conducted in West Africa in
areas of seasonal malaria transmission, although the transmission
in the two sites in Ghana was perennial with seasonal peaks
(Table 1). The estimated Entomological Inoculation Rate in the
study areas ranged from less than 10 up to 137 infectious bites per
person per year. The incidence of malaria in the placebo group
during the transmission season was relatively low in Farafenni and
Basse, The Gambia and Hohoe, Ghana but higher in Kati Region
Figure 1. Flow Diagram of Study Selection Process.
doi:10.1371/journal.pone.0016976.g001
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and Kambila, Mali, Bousse´, Burkina Faso and Niakhar, Senegal.
Usage of bednets was low (,5–22%) in three study sites [20,21,22]
and, at these sites, nets were usually in a bad condition or un-
treated. However, in Basse [19] and Farafenni [23] usage of ITNs
was relatively high (68% and 93%, respectively). In two studies
conducted in Bousse´ [13] and Kati Region [12], all study
participants received ITNs on entry into the study and surveys
found ITN usage to be over 93% and 99%, respectively.
IPTc was administered either monthly or every 2 months and
the number of courses (between 2 and 6) was tailored to the
duration of the malaria transmission season. In all studies, except
for one (Tivaouane), the intervention was implemented for only
one transmission season. A variety of anti-malarial drugs were
used, either alone or in combination. Standard adult tablets were
used throughout. All studies reported that study drugs had greater
than 90% efficacy when used for treatment of patients (children or
adults) with uncomplicated but symptomatic malaria in the study
area. Two efficacy studies (Hohoe [22] and Farafenni [23]) utilised
community health workers (CHWs) to deliver IPTc; in the other
studies, IPTc was delivered in routine health facilities by dedicated
study staff. In all efficacy studies, over 75% of children received at
least the first dose of each IPTc round.
In the majority of the studies, two cross-sectional surveys were
carried out during the intervention year; one at baseline and
another at the end of the intervention period. Either passive
[19,22,23] or both passive and active case detection [12,13,20,21]
took place during the intervention period, which began at the time
of administration of the first IPTc course and ended 4–6 weeks
after the last IPTc course had been given. Surveillance was
continued through the intervening dry season in four studies
(Bousse´, Hohoe, Kambila and Kati [12,13,21,22]) and during the
subsequent malaria transmission season in five (Bousse´, Hohoe,
Kambila, Kati and Niakhar [12,13,20,21,22]), although data for
the second year of follow-up for the Bousse´ and Kati Region trials
were not yet available at the time of data analysis. Methods used to
assess the safety of IPTc varied across studies. In all studies,
Table 1. Characteristics of Controlled Studies.
Cisse
(2006) [20]
Kweku
(2008) [22]
Dicko
(2008) [21]
Bojang
(2010) [19]
Dicko
(2011) [12]
Konate´
(2011) [13]
Sesay
(2011) [23]
Location Niakhar,
Senegal
Hohoe,
Ghana
Kambila,
Mali
Basse,
Gambia
Kati Region,
Mali
Bousse´,
Burkina Faso
Farafenni
Gambia
Entomological inoculation
rate (per person per year)
10 65 137 1–50 7–37 11–74 ,10
Bednet usage 22% any net 11% ITN ,5% any net 68% ITN .99% ITN 93% ITN 93% ITN
IPTc Drugs AS+SP SP bimonthly AS+AQ
bimonthly, AS+AQ
SP bimonthly SP+AQ, SP+PQ,
DHA+PQ
SP+AQ SP+AQ SP+AQ
Delivery Trial staff at
facility
CHW Trial staff at
facility
Trial staff at facility Trial staff at
facility
Trial staff at
facility
CHW
Control Placebo Placebo Nothing Non-randomised
arm
Placebo & ITN Placebo & home
management of
malaria
AQ: amodiaquine, AS: artesunate, CHW: community health worker, DHA: dihydroartemisinin, ITN: insecticide treated bednet, PQ: piperaquine, SP: sulphadoxine
pyrimethamine.
doi:10.1371/journal.pone.0016976.t001
Table 2. Characteristics of Non-controlled Studies.
Sokhna
(2008) [24]
Cisse
(2009) [25]
Bojang
(2011) [26]
Kweku
(2009) [27]
Cisse
(unpublished) [28]
Location Niakhar, Senegal Ndoffane, Senegal Basse, The Gambia Jasikan, Ghana Tivaouane, Senegal
Entomological
inoculation rate
(per person per year)
10 Not known 1–50 65 10
Bednet usage 18% slept under
intact or
impregnated net
29% slept under
intact or
impregnated net
50%/62% slept under intact
or impregnated net in
Reproductive and Child
Health trekking team and
CHW arms, respectively
19% bednet usage, 14%
ITN usage
28% bednet usage,
13% ITN usage
IPTc Drugs SP+1AS monthly
SP+3AS monthly
AQ+3AS monthly
SP+AQ monthly
SP+AQ monthly
DHA+PQ monthly
SP+PQ monthly
SP+AQ monthly SP+AQ (May/Jun./Sept./Oct) SP+AQ monthly
Delivery Study staff CHW CHW or Reproductive and
Child Health trekking team
Health facility (routine staff with
support) or CHW
CHW
AQ: amodiaquine, AS: artesunate, CHW: community health worker, DHA: dihydroartemisinin, ITN: insecticide treated bednet, PQ: piperaquine, SP: sulphadoxine
pyrimethamine.
doi:10.1371/journal.pone.0016976.t002
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physicians were available to assess any events which arose during
the period of follow up. In addition, all children, or a random
sample of children, were questioned or a standardised question-
naire was administered following the first or all courses of IPTc to
identify any AEs. In one study (Niakhar), children were physically
examined. In the Kambila study, only the incidence of SAEs was
recorded.
Controlled studies were generally of high quality (Table 3). Four
studies were placebo controlled and double blind (Niakhar [20];
Bousse´ [13]; Kati Region [12] and Farafenni [23]). In one placebo-
controlled study (Hohoe) [22] the lead investigator was accidentally
un-blinded. In another study (Kambila [21]) children in the control
arm received no intervention. In both these cases there may have
been potential for introduction of bias. In Basse [19], a non-
randomised cohort of children of the same age group from
neighbouring villages was used as a reference group for comparisons
of malaria incidence and safety. In this study, there was also
potential for introduction of bias due to a higher loss to follow up in
the SP+amodiaquine (AQ) arm (22%) compared to the other arms
(11–12%). The reason for this difference in attrition is unclear since
there was no obvious difference in the characteristics of the groups
of children and the incidence of AEs in children in the SP+AQ arm
was similar to that recorded in children in the other arms of the trial.
Non-controlled trials were all non-blinded and so there was a risk of
introduction of bias in these studies.
Efficacy of IPTc
The PE of IPTc with SP monotherapy administered every 2
months against uncomplicated clinical malaria (any parasite
density) was 35% (95%CI: 17–48%) in Ghana and 69%
(95%CI: 54–80%) in Mali (Table 4). Artesunate (AS)+AQ
administered bimonthly in Ghana had the lowest PE of any drug
regimen investigated (31%; 95%CI: 13–46%), but this drug
regimen administered monthly had a much higher PE (75%;
95%CI: 65–82%). SP+AS had a PE of 83% (95%CI: 79–86%) in
Senegal. The PE of SP+AQ given monthly was consistently high,
ranging from 71% (95%CI: 68–74%) in Burkina Faso, to 93%
(95%CI: 79–97%) in The Gambia. The PE of SP+piperaquine
(PQ) in The Gambia was 93% (95%CI: 80–97%). The PE of
SP+AQ administered monthly in the Kati and Bousse´ region trials,
in which ITNs were also given to each child at the onset of the
trial, was 83% (95%CI: 80–86%) and 71% (95%CI: 68–74%),
respectively. The very low number of malaria episodes in
Farafenni precluded any meaningful interpretation of the effect
of IPTc (SP+AQ) on clinical malaria in this study (PE: 49%,
95%CI: 2459–95%). The rate difference was highest in Kambila,
Mali at 4544 episodes per 1000 children due to the high incidence
of clinical malaria in the control arm in this study. The rate
difference was also high in Niakhar, Bousse´ and Kati Region at
3681, 2671 and 1996 clinical malaria episodes per 1000 PYAR,
respectively. The rate difference was lowest in Farafenni at 6
episodes per 1000 PYAR.
Random effect meta-analysis of all studies gave a summary rate
ratio of 0.25 (95%CI: 0.17–0.36) (Figure 2) and restricting the
meta-analysis to studies in which IPTc was delivered monthly gave
a summary rate ratio of 0.18 (95%CI: 0.13–0.25, p,0.001) which
is equivalent to a summary PE of 82% (95%CI: 75–87%). Use of
fixed effect meta-analysis or a more specific malaria case definition
which included a locally defined parasite threshold did not alter
the results appreciably (data not shown).
Data on severe malaria were available only for two trials (Kati
Region [12] and Bousse´ [13]) which were conducted in parallel
and designed to have sufficient power to assess this outcome when
the data were pooled. There were 4 and 22 cases of severe malaria
Table 3. Assessment of risk of bias in studies.
Study Site
Adequate sequence
generation
Allocation
assignment
Blinding of partic-
ipants, personnel
and outcome
assessors
No evidence of
incomplete
outcome data
No evidence
of selective
outcome
reporting
Cisse (2006) [20] Niakhar Yes Yes Yes (double blind) Yes Yes
Kweku (2008) [22] Hohoe Yes Yes No (drug packers and
principal investigator
un-blinded)
Yes Yes
Dicko (2008) [21] Kambila Yes Yes No (open label, control
arm received no
intervention)
Yes Yes
Bojang (2010) [19] Basse No (control arm for
malaria incidence/safety
comparison non
randomised)
Yes No (open label) No (higher loss to
follow up in SP+
AQ arm, 22% vs
11–12%, no
obvious explanation)
Yes
Dicko (2011) [12] Kati Region Yes Yes Yes (double blind) Yes Yes
Konate´ (2011) [13] Bousse´ Yes Yes Yes (double blind) Yes Yes
Sesay (2011) [23] Farafenni Not assessed (information not available)
Sokhna (2008) [24] Niakhar No (villages chosen for logistical convenience,
systematic allocation of individual children)
No (open label) Yes Yes
Cisse (2009) [25] Ndoffane Yes Yes No (open label) Yes Yes
Bojang (2011) [26] Basse Yes Yes No (open label) Yes Yes
Kweku (2009) [27] Jasikan Yes Yes No (open label) Yes Yes
Cisse [28] (unpublished) Tivaouane Not assessed (information not available)
AQ: amodiaquine, SP: sulphadoxine pyrimethamine.
doi:10.1371/journal.pone.0016976.t003
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detected in intervention and placebo groups, respectively, giving a
PE of 82% (95%CI: 48–94%, p= 0.002). There was also evidence
of a substantial reduction in the incidence of all-cause hospital
admissions in these two trials; 27 children were admitted to
hospital in the IPTc group compared with 45 in the placebo group
(PE: 41%, 95%CI: 5–63%, p= 0.03).
Table 4. Effect of IPTc on clinical malaria during the intervention period.
Study Site Drug Regimen
No. of
children
Definition of clinical malaria (fever or history of fever plus any level of
parasitaemia)
No. of episodesA
Incidence Rate
per 1000 PYAR
Rate Difference
per 1000 PYAR PE (95% CI)
Cisse (2006) [20] Niakhar SP+AS 542 96 758 3681 83 (79–86)
Placebo 546 438 4439 -
Kweku (2008) [22] Hohoe SP bimonthly 613 112 403 214 35 (17–48)
AS+AQ bimonthly 562 109 425 192 31 (13–46)
AS+AQ monthly 626 44 153 464 75 (65–82)
Placebo 650 183 617 -
Dicko (2008) [21] Kambila SP bimonthly 58 30 2000 4544 69 (54–80)
Control 59 86 6544 -
Bojang (2010) [19] Basse SP+AQ 336 4 58 733 93 (79–97)
SP+PQ 336 4 57 734 93 (80–97)
DHA+PQ 336 7 103 688 87 (71–94)
Control 286 41 791 -
Dicko (2011) [12] Kati Region SP+AQ 1509 149 411 1996 83 (80–86)
Placebo 1508 832 2407 -
Konate´ (2011) [13] Bousse´ SP+AQ 1509 416 1114 2671 71 (67–74)
Placebo 1505 1232 3785 -
Sesay (2011) [23] Farafenni SP+AQ 639 1 5 6 49 (2459–95)
Placebo 638 2 11
ATotal number of clinical malaria episodes, AQ: amodiaquine, AS: artesunate, CI: confidence interval, DHA: dihydroartemisinin, PE: protective efficacy, PQ: piperaquine,
PYAR: person years at risk, SP: sulphadoxine pyrimethamine.
doi:10.1371/journal.pone.0016976.t004
Figure 2. Effect of IPTc on clinical malaria (any level of parasitaemia) during the intervention period. NOTE: D+L Overall = Random effect
meta-analysis, I–V Overall = Fixed effect meta-analysis. AQ: amodiaquine, AS: artesunate, bi: bimonthly administration, CI: confidence interval, DHA:
dihydroartemisinin, PQ: piperaquine, SP: sulphadoxine pyrimethamine.
doi:10.1371/journal.pone.0016976.g002
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Pooling of data across twelve studies [12,13,19,20,21,22,
23,24,25,26,27,28] indicated that there were 47 deaths (all-cause)
among 35,350 children in the IPTc arms compared to 16 deaths
per 5,186 children in the control arms during the intervention
period. This gives a PE of IPTc against all-cause mortality of 57%
(95%CI: 24–76%, p= 0.003) during the intervention period.
Pooling of mortality data across eight studies [12,13,19,20,
21,22,26,27] which reported person time at risk, showed that
children receiving IPTc had 0.51 times the rate of all-cause
mortality compared to children in control arms during the
intervention period (95%CI 0.28–0.95, p = 0.03).
In the trials conducted in Kati Region and Bousse´ [12,13],
children who received IPTc with SP+AQ had a significantly
lower prevalence of anaemia and higher mean Hb concentration
at the end of the intervention period compared to children who
received placebo (Table 5). In contrast to these findings, no
significant difference in mean Hb/Hct concentration was
observed at the end of the intervention period in the three other
studies which assessed this endpoint [21,22,23]. Meta-analysis of
the prevalence of anaemia in five studies showed no overall
positive effect of IPTc (Risk ratio: 0.84, 95%CI: 0.59–1.21,
p = 0.36) [12,13,20,21,22].
In three studies [12,13,20], there was a highly significant
reduction in the prevalence of parasitaemia in the IPTc arm at
the end of the intervention period (Table 6). In an additional
study [21], there was evidence of a lower prevalence of
parasitaemia in the IPTc arm compared to the control but the
sample sizes were relatively small. Data from Hohoe [22]
indicated that bimonthly administered IPTc was less effective at
reducing parasitaemia at the end of the intervention period
compared to monthly administered IPTc. In one study
conducted in Farafenni, The Gambia [23] the prevalence of
parasitaemia was very low and was similar among IPTc and
control children at both the pre- and post-intervention surveys.
Meta-analysis of the prevalence of parasitaemia in six studies
which assessed this endpoint showed a positive effect of IPTc
(Risk ratio: 0.47, 95%CI: 0.30–0.75, p = 0.002) [12,13,20,
21,22,23].
Safety of IPTc
No drug-related SAEs were observed during the intervention
period in which a total of 100,767 IPTc courses were delivered to
35,350 children. No cases of Stevens Johnson syndrome were seen
in the 32,757 children who received SP or SP-containing
regimens, and no cases of serious blood dyscrasias or liver damage
in the 31,327 children who received AQ-containing combinations.
The prevalence of AEs varied greatly between individual
studies, especially for vomiting which was the most commonly
reported AE. Thus, care is needed in the interpretation of the
results of comparisons between treatment regimens when
combined data from several trials are used. Nevertheless, some
general observations can be made (Table S4). Vomiting was
reported most frequently following administration of SP+PQ,
DHA+PQ and SP+AQ. Fever, headache and pruritus were also
reported more frequently following administration of these
regimens. Administration of SP+PQ and DHA+PQ was associated
with increased reports of minor skin rash and coughing compared
to children in control arms. AS+AQ was associated with a low
incidence of AEs, with only reports of drowsiness and abdominal
pain being significantly raised compared to control children.
SP+AS was well tolerated and was associated with the lowest
incidence of AEs overall.
In studies in which alternative drug regimens were compared,
vomiting was reported more frequently following administration of
AQ- containing regimens than other regimens. For example in
Ndoffane, Senegal, vomiting was reported more frequently
following administration of SP+AQ than DHA+PQ or SP+PQ [25].
A concern of any form of community wide drug administration
is that it will encourage the emergence of drug resistant parasites.
In the study conducted in Niakhar, the prevalence of the dhfr triple
mutation and the dhps mutation increased substantially in both
IPTc and placebo arms during the intervention period (Table 6)
[20]. At the post-intervention survey, the proportion of para-
sitaemic children carrying parasites with the dhfr triple mutation
and the dhps mutation was higher in children in the SP+AS arm
than in the placebo arm (dhfr: SP+AS 95%, placebo 75%, p= 0.01
and dhps: SP+AS 86%, placebo 44%, p,0.001). However, as the
Table 5. Effect of IPTc on mean haemoglobin/haematocrit concentrations in intervention and control arms at the end of the
intervention period.
Study Site Drug Regimen No. children
Mean Hb (g/dL)/Hct (%)
concentration [95% CI] p-value (z-test)
Kweku (2008) [22] Hohoe SP bimonthly 550 9.2 (6.6–11.8) 0.20
AS+AQ bimonthly 464 9.2 (6.6–11.8) 0.23
AS+AQ monthly 559 9.4 (7.0–11.8) 0.18
Placebo 589 9.3 (6.7–11.9) -
Dicko (2008) [21] Kambila SP bimonthly 55 32.1 (31.2–33.0) 0.80
Control 54 31.9 (31.0–32.8) -
Dicko (2011) [12] Kati Region SP+AQ 1422 11.0 (10.7–11.2) 0.06
Placebo 1433 10.7 (10.5–10.9) -
Konate´ (2011) [13] Bousse´ SP+AQ 1444 11.0 (10.9–11.1) ,0.001
Placebo 1441 10.4 (10.3–10.4) -
Sesay (2011) [23] Farafenni SP+AQ 513 10.2 (7.1–13.3) 0.79
Placebo 533 10.3 (7.4–13.2) -
AQ: amodiaquine, AS: artesunate, CI: confidence interval, DHA: dihydroartemisinin, Hb: haemoglobin, Hct: haematocrit, PQ: piperaquine, SP: sulphadoxine
pyrimethamine.
doi:10.1371/journal.pone.0016976.t005
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prevalence of parasitaemia in the children who received IPTc was
overall much lower than that in children in the placebo group, the
estimated prevalence of drug resistant parasitaemia among study
children was lower in the SP+AS arm than in the placebo arm
(dhfr: SP+AS 13%, placebo 28% and dhps: SP+AS 12%, placebo
16%). Data on the prevalence of drug resistance markers in the
second year of follow-up was only available for the study
conducted in Niakhar. In this study, the difference in the
prevalence of markers of resistance to SP was lost at the end of
the second year of follow-up (dhfr: SP+AS 88%, placebo 86%,
p= 0.69 and dhps: SP+AS 64%, placebo 77%, p= 0.10). In the
Kati Region, the prevalence of the dhfr triple and dhps mutations
was higher in the IPTc arm compared to the placebo arm at the
post intervention survey [12]. However, the estimated prevalence
of drug resistant parasitaemia among study children was
comparable in the SP+AQ arm and placebo arms (dhfr triple
mutation SP+AQ 5%, placebo 6% and dhps 437 mutation SP+AS
6%, placebo 8%). In a further two studies (Bousse´ and Hohoe), the
proportion of parasites carrying SP resistance markers was similar
in IPTc and placebo arms at the post-intervention survey [13,22].
A further safety concern for IPTc is that it will impair the
development of natural immunity making children more suscep-
tible to malaria after treatment is stopped. At the time of this
review, data on clinical outcomes in the year after administration
of IPTc were available for only three studies [20,21,22]. None of
these studies demonstrated a statistically significant increase in the
incidence of clinical malaria during the transmission season
following the intervention. Random effect meta-analysis gave a
summary effect measure of 1.11 (95% CI 0.99–1.24, p= 0.07)
(Figure 3). A similar result was obtained when a more specific
malaria case definition was used (data not shown). At the end of
the malaria transmission season in year 2, the prevalence of
anaemia in children who had received SP+AS in Niakhar was
higher than in children who had received placebo in year 1
Table 6. Effect of IPTc on prevalence of parasitaemia, dhps and dhfr resistance markers measured at cross sectional surveys during
the intervention year.
Study Arm
Children with
asexual
ParasitaemiaA
% (N) p-valueB Parasite carriage of resistance markers
Estimated minimum
prevalence of resistant
parasitaemia amongst
children
dhfr triple
mutation
% (N) p-valueB
dhps 437
mutation
% (N) p-valueB
dhfr triple
mutation %
dhps 437
mutation
%
Pre-intervention
Cisse (2006) [20] Niakhar SP+AS 37 (516) 0.77 51 (71) 0.06 28 (67) 0.92 19 10
Placebo 36 (512) - 67 (69) - 29 (72) - 24 11
Dicko (2008) [21] Kambila SP bimonthly 36 (53) 0.14 - - - - - -
Control 23 (53) - - - - - - -
Dicko (2011) [12] Kati Region SP+AQ - - 59 (41) - 38 (41) - - -
Placebo - - - -
Konate´ (2011) [13] Bousse´ SP+AQ - - 33 (132) - - - -
Placebo - - - -
Sesay (2011) [23] Farafenni SP+AQ 0.5 (639) 0.99 - - - - - -
Placebo 0.5 (638) - - - - - - -
Post-intervention
Cisse (2006) [20] Niakhar SP+AS 14 (440) ,0.001 95 (41) 0.01 86 (28) ,0.001 13 12
Placebo 37 (446) - 75 (122) - 44 (89) - 28 16
Kweku (2008) [22] Hohoe SP bimonthly 16 (550) 0.14 90 (51) 0.41 63 (54) 0.33 14 10
AS+AQ
bimonthly
22 (464) 0.29 84 (55) 0.86 63 (51) 0.35 18 14
AS+AQ monthly 5 (559) ,0.001 92 (13) 0.49 45 (11) 0.62 4 2
Placebo 20 (589) - 85 (53) - 54 (54) - 17 11
Dicko (2008) [21] Kambila SP bimonthly 4 (55) 0.04 - - - - - -
Control 15 (54) - - - - - - -
Dicko (2011) [12] Kati Region SP+AQ 7 (1405) ,0.001 49 (83) 0.02 68 (83) ,0.001 5 6
Placebo 13 (1423) - 34 (160) 44 (165) 6 8
Konate´ (2011) [13] Bousse´ SP+AQ 11 (1436) ,0.001 50 (114) 0.61 6 -
Placebo 42 (1430) - 53 (122) 22 -
Sesay (2011) [23] Farafenni SP+AQ 0.6 (513) 0.52 - - - - - -
Placebo 0.9 (533) - - - - - - -
AAny density parasitaemia,
BChi2 test, AQ: amodiaquine, AS: artesunate, DHA: dihydroartemisinin, N = total number of samples analysed, PQ: piperaquine, SP: sulphadoxine pyrimethamine.
doi:10.1371/journal.pone.0016976.t006
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(SP+AS 10%, placebo 6%, p= 0.02) [20]. However, the mean Hb
concentration (g/dL, 95%CI) was similar in SP+AS and placebo
arms (SP+AS: 9.4 (9.3–9.6), placebo: 9.6 (9.4–9.6), p = 0.24). The
prevalence of anaemia was similar in IPTc and placebo arms of
the Hohoe trial at the end of the transmission season in the post-
intervention year (SP bimonthly 12%, AS+AQ bimonthly 15%,
AS+AQ monthly 10%, placebo 12%) [22]. The prevalence of
parasitaemia at the end of the transmission season in the post-
intervention year was similar among children who received IPTc
or placebo in the previous year in the Niakhar and Hohoe studies
(Niakhar: SP+AS 28%, placebo 30%, Hohoe: SP bimonthly 39%,
AS+AQ bimonthly 40%, AS+AQ monthly 42%, placebo 40%)
[20,22].
Discussion
As with any retrospective study of this kind, this review has a
number of limitations. It is possible that the literature search may
have missed some studies. However, we consider that this is
unlikely as the group of scientists involved in the study of IPTc is
small and personal enquiries from those known to be active in the
field, as well as formal literature searches, were undertaken.
Heterogeneity in study design and findings makes some compar-
isons, for example those on the occurrence of AEs, difficult. Since
the reviewers did not have access to individual patient data, the
effect of study/patient characteristics, such as baseline parasitae-
mia, age or ITN usage, on clinical outcomes could not be assessed.
Study quality was variable but the small number of IPTc studies
identified limited the extent to which sensitivity analysis could be
conducted. However, an attempt was made to increase the
robustness of the meta-analysis by assessing the effect on PE of
using different malaria definitions and using both fixed and
random effect meta-analysis. The meta-analysis focused on total
malaria episodes, the important public health outcome, rather
than first episodes so it may have overestimated PE for this
endpoint. Despite these limitations we believe that this review
provides a valid overview of current knowledge on the potential of
IPTc as a malaria control tool.
All of the controlled studies identified demonstrated a protective
effect of IPTc against clinical episodes of malaria during the
malaria transmission season ranging from 31% to 93%; the overall
PE of IPTc administered monthly was 82%. Analysis of the
efficacy trials allows some conclusions to be made about the
efficacy of individual drugs and dosing regimens in preventing
episodes of clinical malaria. The highest PE was observed using
two drugs with a long half-life in combination, SP+AQ or SP+PQ.
Long acting drugs used alone or in combination with short acting
drugs, such as AS or DHA showed lower PEs. No advantage was
seen from the use of artemisinin combination therapies, which
should probably be reserved for treatment of clinical malaria when
the rapid action of artemisinins is of particular benefit. As would
be expected, bimonthly administration of SP or AS+AQ
demonstrated a lower PE than monthly IPTc administration.
The results add weight to the growing body of evidence which
suggests that IPT works largely by providing a period of post-
treatment prophylaxis and that the length of this period of
protection is determined by the pharmacodynamics of the drugs
used [29].
None of the trials was individually powered to demonstrate an
effect on severe malaria or all-cause mortality. However, pooled
data from Kati Region and Bousse´ showed a PE of 82% against
severe malaria and data from twelve studies suggests that
administration of IPTc reduced overall mortality in children aged
3–59 months by more than 50% during the intervention period.
These results are supported by a study in The Gambia, which
deployed fortnightly chemoprophylaxis with pyrimethamine/
dapsone during the malaria transmission season, and demonstrat-
ed an approximately 40% reduction in overall mortality in
children in the same age range [30]. The PE of IPTc against all-
cause mortality over the whole year will have been lower than the
PE during the high transmission season, but in countries of the
Sahel and sub-Sahel a high proportion of deaths occur during the
high transmission season [4,5,31,32]. The studies reviewed here
may have underestimated the protective effect of IPTc against all-
cause mortality as a result of close monitoring of all study children,
including those in control arms. In contrast, effectiveness of IPTc
Figure 3. Effect of IPTc on clinical malaria (any level of parasitaemia) during the subsequent transmission season (following IPTc
administration). NOTE: D+L Overall = Random effect meta-analysis, I–V Overall = Fixed effect meta-analysis. AQ: amodiaquine, AS: artesunate, bi:
bimonthly administration, CI: confidence interval, SP: sulphadoxine pyrimethamine.
doi:10.1371/journal.pone.0016976.g003
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against all-cause mortality may be lower than that observed in
controlled studies if IPTc were to be deployed routinely in a public
health programme. The apparent impact of IPTc on mortality
revealed by this review is impressive. However, these findings
should be treated with caution as the number of deaths was small.
A large, community randomised trial of IPTc currently under way
in Senegal will provide further information on the impact of IPTc
on all-cause mortality, although the overall level of malaria
transmission has fallen substantially in the study area since the trial
was planned and this may reduce the statistical power of this study
(B. Cisse, personal communication).
Two of the five studies which assessed the effect of IPTc on the
prevalence of anaemia and mean Hb levels demonstrated a
beneficial effect. The lack of effect in other studies may have been
due in part to the fact that children were kept under close
observation, so episodes of malaria or anaemia were detected and
treated promptly during the course of the intervention period, and
partly due to the varying importance of malaria as a contributory
factor to the pathogenesis of anaemia in different epidemiological
settings [13].
Three aspects of the safety of IPTc have been considered in this
review – immediate toxicity, facilitation of the spread of drug
resistance and impairment of naturally acquired immunity.
No SAEs which could be attributed to administration of drugs
for IPTc were recorded. In particular, no cases of Stevens Johnson
syndrome were observed in the 32,757 children who received SP
or SP-containing regimens. These observations confirm reports of
the safety of SP when used for IPT in infants [3]. Concerns about
the safety of AQ followed the occurrence of serious haematological
and hepatic side effects in travellers when the drug was used for
chemoprophylaxis. No cases of hepatic failure were recorded in
the children included in the studies covered by this review but
minor degrees of damage cannot be excluded because liver
function tests were not undertaken routinely. A review of a large
number of patients included in trials of AQ-containing regimens
used for treatment of clinical episodes of malaria in both adults
and children concluded that the drug is safe when used in this
context [33].
The most commonly recorded AEs were fever and vomiting,
which were reported most often following administration of
SP+PQ, DHA+PQ and SP+AQ. Vomiting may have been
misreported when children spat out AQ or PQ tablets in reaction
to their bitter taste. In the study conducted in Jasikan, Ghana [27],
there was a reduction in the incidence of AEs at each round of
drug administration. In Jasikan, vomiting of the study drugs was
successfully mitigated by coaching caretakers to feed the children
sugary food at the time of drug administration. It may also be
possible to reduce the incidence of vomiting caused by AQ
through better dosing and production of tablets with a drug
content optimised for use in IPTc. Analysis of data from two IPTc
studies conducted in Senegal showed that the incidence of
vomiting was most marked in children who were overdosed,
because of the dose stratification used, and that it should be
possible to reduce the occurrence of vomiting by adjusting the dose
[34]. It will be important to minimise the incidence of even minor
AEs as these could reduce uptake and compliance with IPTc.
Extensive use of anti-malarials for prevention adds to drug
pressure and carries some risk of facilitating the emergence and
spread of drug resistant parasites. Drug pressure will be higher
when a drug is used for IPTc, covering up to 20% of the
population, than when used for IPT in infants or pregnant women
(2–5% of the population). Some evidence to support the view that
IPTc with SP-containing regimens will select resistant parasites
was obtained from the study in Niakhar, Senegal where the
proportion of parasites carrying markers of resistance to SP was
higher at the end of the malaria transmission season in children
who had received IPTc than in children who had received
placebo. However, although the proportion was higher, the
prevalence of resistant parasitaemia in children who had received
IPTc was lower than that in control children because of the effect
of IPTc in reducing the overall prevalence of parasitaemia in these
children. Which of these variables is most relevant to the spread of
drug resistance is uncertain. It was reassuring that by the following
year the difference between groups had been lost, suggesting that
the parasites carrying resistance markers were at a biological
disadvantage in the absence of drug pressure. Nevertheless, if IPTc
is sustained for a period of many years it will exert significant drug
pressure on the parasite population; use of a combination of drugs
rather than a monotherapy should help to mitigate this risk and
use of the same drugs for both first-line treatment and IPTc should
be avoided whenever possible.
As for any other successful malaria control measure, an effective
IPTc regimen will reduce exposure to malaria parasites and thus
has the potential to impair the development of naturally acquired
immunity. Meta-analysis indicated a small increase in the
incidence of clinical malaria episodes during the malaria
transmission season in the year following IPTc administration
among children who received IPTc compared to control children.
In Niakhar, a small increase in the prevalence of anaemia was
observed in children who had received IPTc in the previous year
but no significant effect on mean Hb concentration was observed
so this may have been a chance finding. Unpublished results from
Kati Region, Mali and Bousse´, Burkina Faso also indicate a slight
rebound effect on clinical malaria among children who received
IPTc (D. Diallo, personal communication). The 12 month
incidence of clinical malaria in the placebo arms of the studies
conducted in Kati Region and Bousse´ indicates that approxi-
mately 10% of episodes occur outside the high transmission
season. Taking these two factors into account, the PE of IPTc
against clinical malaria defined using a parasite threshold of 5000
asexual forms of P. falciparum per mL was reduced from 82% during
the high transmission season to 63% during the whole 12 month
period in Mali and similarly from 70% to 49% during the whole
12 month period in Burkina Faso.
A limitation of the efficacy studies is that IPTc was only
administered for only one transmission season. It is likely that if
children are given IPTc each year for their first five years of life
this will have a greater impact on the development of naturally
acquired immunity to malaria. This was observed in The Gambia
when fortnightly chemoprophylaxis during the rainy season was
given each year for many years [35]. In this Gambian study there
was an increase in the incidence of clinical attacks of malaria in the
year after the intervention was stopped which was most marked in
children who had received chemoprophylaxis during each of the
first five years of life. There was, however, no significant rebound
in deaths but the number of deaths was small. IPTc may allow
greater exposure to malaria parasites than chemoprophylaxis thus
facilitating the development of some naturally acquired immunity
but if IPTc is widely deployed surveillance for a potential rebound
effect will need to be maintained.
Based on the data reviewed, IPTc offers young children a high
level of protection against clinical malaria and appears to
substantially reduce mortality during the malaria transmission
season. Widespread deployment of IPTc will inevitably cause some
drug related side effects, may enhance drug resistance and, like all
effective malaria control measures, may lead to some loss of
naturally acquired immunity. Balancing these benefits and risks
will require careful assessment of the burden of malaria in a
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particular community, its seasonality and the sensitivity of the
prevalent parasites to the drugs currently available for use in IPTc.
Implementation of IPTc should now be considered as part of an
integrated malaria control strategy in areas of seasonal malaria
transmission. In considering introduction of IPTc as a malaria
control policy it will also be important to assess the acceptability,
feasibility, sustainability, cost and cost effectiveness of the
intervention. Research that investigates some of these aspects of
IPTc is underway [26,36] and this topic will be the subject of a
further review.
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